Abstract 69P
Background
PPIs taken before ICI may worsen outcomes in pts with solid tumors due to their gut microbiome disruptive effects, although no clear dose-dependent effect has been established yet.
Methods
We assessed the dose-dependent effects of PPIs on clinical outcomes in pts with stage IV solid tumors treated with PD-1/PD-L1 inhibitors at 17 Italian institutions from June 2014 to May 2020. PPI potency was standardized using the omeprazole equivalency (OE) method by Kirchheiner et al. An optimal OE cut-off was determined via the Youden index, categorizing pts into no PPI, low-potency PPI (≤13.5 mg/day OE), and high-potency PPI (>13.5 mg/day OE).
Results
Of the 675 pts included, 179 (26.5%) were on PPIs at baseline: 11.4% on low-potency and 15.1% on high-potency. Pts on PPIs were generally older, had poorer performance status (PS), higher disease burden, more baseline corticosteroid use, advanced-line treatment, and typically had non-small cell lung cancer. High-potency PPIs were associated with significantly worse overall survival (OS) (HR 1.55; 95% CI: 1.17-2.05) and progression-free survival (HR 2.02; 95% CI: 1.59-2.55) compared to no PPIs. Low-potency PPIs were not significantly associated with adverse outcomes. Multivariable Cox regression confirmed that only high-potency PPIs were associated with an increased risk of death (HR 1.55; 95% CI: 1.17-2.05), even after adjusting for potential confounders such as age, gender, PS, histology, disease burden, treatment line and baseline corticosteroid use. Double-adjusted propensity score matching confirmed the association between high-potency PPIs and poorer OS (HR 1.41; 95% CI: 1.04-1.92).
Conclusions
High-potency PPIs at baseline are associated with worse outcomes in pts treated with ICIs for stage IV solid tumors. Although further investigation is needed, these results suggest that PPIs should be used at the lowest effective dose to minimize potential detrimental effect.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
168TiP - A phase I dose escalation/expansion study of GSK5764227 (GSK’227), a B7-homolog 3 (B7-H3) protein targeted antibody-drug conjugate (ADC), in patients with advanced solid tumours
Presenter: Giuseppe Curigliano
Session: Poster Display session
Resources:
Abstract
169TiP - Colorectal carcinoma: Low dose immunotherapy in upfront metastatic d/MMR patients (CLOUD study)
Presenter: Anant Ramaswamy
Session: Poster Display session
Resources:
Abstract
177P - Ubiquitous neoantigens as targets for T cell recognition in a patient with metastatic pancreatic neuroendocrine tumour
Presenter: Jean-Benoit Tanis
Session: Poster Display session
Resources:
Abstract
178P - Comprehensive immunophenotype analysis in anti-PD-1 antibody sensitive and resistant syngeneic mouse model unravels perforin-expressing CD4+T cells dominant cytolytic activity
Presenter: Hiroyuki Inoue
Session: Poster Display session
Resources:
Abstract
179P - Impact of exercise training on tumour-infiltrating T cells in human prostate cancer
Presenter: Louise Lehrskov
Session: Poster Display session
Resources:
Abstract
180P - Chronic circadian disruption promotes melanoma progression by interfering with NK cells
Presenter: Shuwen Xiao
Session: Poster Display session
Resources:
Abstract
181P - Intratumoral heterogeneity of immune infiltrate in leiomyosarcomas
Presenter: Iva Benesova
Session: Poster Display session
Resources:
Abstract
182P - Innovative nano-immunotherapy for modulating tumor-immune interactions and microbiome in pancreatic cancer
Presenter: Liane Moura
Session: Poster Display session
Resources:
Abstract
183P - CAIX negatively modulates inflammatory and anti-tumor immune responses
Presenter: Eliska Svastova
Session: Poster Display session
Resources:
Abstract
184P - Alterations in tumorigenicity and immunogenicity of bladder cancer cells after somatic cell reprogramming
Presenter: Banu Iskender Izgi
Session: Poster Display session
Resources:
Abstract